Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07848295 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

Name: A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) — clinical trial record (NCT07848295)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

Started2026-12-31

View on ClinicalTrials.gov ↗

Bristol-Myers Squibb

311 trials monitored

See 15 trials at risk

Kidney Cancer

770 trials monitored

See 52 trials at risk

The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)

Trial Details

NCT Number	NCT07848295
Lead Sponsor	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Collaborators: Bristol-Myers Squibb
Conditions	Clear Cell Renal Cell Carcinoma (ccRCC)
Enrollment	112 participants
Start Date	2026-12-31
Primary Completion	2030-10-18 (estimated)
Study Completion	2031-04-17 (estimated)
Updated on ClinicalTrials.gov	2026-09-30